Clinical Trial Update: A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA) [Phase 3]

View source ↗

Summary

This is a Phase 3 long-term extension study evaluating subcutaneous tocilizumab in adults with moderate-to-severe rheumatoid arthritis; results were posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Actemra (tocilizumab) (tocilizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2016-10-12